Shares of Jazz Pharmaceuticals PLC (JAZZ) extended their losses in after-hours trading on Tuesday, plummeting 6.89% following the release of the company's disappointing first-quarter 2025 financial results. The biopharmaceutical firm's earnings and revenue fell significantly short of analysts' expectations, exacerbating concerns among investors after an already challenging regular trading session.

Jazz Pharmaceuticals reported first-quarter revenue of $897.841 million, well below the IBES estimate of $985.4 million. The company's adjusted earnings per share (EPS) came in at $1.68, drastically missing the expected $4.66 per share. This represents a 37.31% decrease compared to the same period last year. Additionally, Jazz's adjusted net income for the quarter was $105.233 million, far lower than the estimated $288.6 million. The company also reported a net loss of $92.541 million, translating to a loss per share of $1.52.

The substantial underperformance across key financial metrics has led to increased scrutiny of Jazz Pharmaceuticals' near-term prospects. The company announced updates to its 2025 financial guidance, which may further contribute to investor uncertainty. As the market continues to digest these results, analysts will likely reassess their projections for Jazz Pharmaceuticals' future performance, potentially impacting the stock's valuation in the coming days. Investors will be closely monitoring the company's strategies to improve performance in subsequent quarters.